Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.
about
Different sources of autologous mononuclear cells and stem cells for critical lower limb ischaemiaStem cells in plastic surgery: a review of current clinical and translational applicationsCell-based interventions for therapeutic angiogenesis: review of potential cell sourcesAutologous bone marrow cell therapy for peripheral arterial diseaseLimb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severityAutologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease.Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells.Clinical application of stem cells for therapeutic angiogenesis in patients with peripheral arterial disease.Thromoboagiitis Obliterans (TAO).Thromboangiitis obliterans.Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease.CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease.No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia.Toward a mouse model of hind limb ischemia to test therapeutic angiogenesisCultured human bone marrow-derived CD31(+) cells are effective for cardiac and vascular repair through enhanced angiogenic, adhesion, and anti-inflammatory effects.A phase II trial of autologous transplantation of bone marrow stem cells for critical limb ischemia: results of the Naples and Pietra Ligure Evaluation of Stem Cells study.Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial.Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia.Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential.Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy.Long-Term Results of Treatment for Critical Limb Ischemia.Adequate Selection of a Therapeutic Site Enables Efficient Development of Collateral Vessels in Angiogenic Treatment With Bone Marrow Mononuclear Cells.A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.Tracking cells implanted into cynomolgus monkeys (Macaca fascicularis) using MRI.Cell therapy in peripheral arterial disease.Critical limb ischemia in a young man: saddle embolism or unusual presentation of thromboangiitis obliterans?Therapeutic strategies for cell-based neovascularization in critical limb ischemiaAutologous bone marrow cell therapy for patients with peripheral arterial disease: a meta-analysis of randomized controlled trials.Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review.Cell therapy for cardiovascular diseases.Biodistribution of locally or systemically transplantedosteoblast-like cells.Pathogenesis and Management of Buerger's Disease.Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell productIntra-arterial autologous bone marrow cell transplantation in a patient with upper-extremity critical limb ischemia.A new role of thrombopoietin enhancing ex vivo expansion of endothelial precursor cells derived from AC133-positive cells.Cardiovascular repair with bone marrow-derived cellsAdvances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factorsGene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease.
P2860
Q24198835-98E40023-0476-4F53-8A76-EFECD9541DB9Q26821935-4E5CF909-03F8-4053-8FCE-327488D802A1Q27022590-7AEE40AC-D1E1-4F16-A3D6-68937F3093D5Q27026719-381F5FB4-1A82-48D7-9FD2-86510EDA9C3DQ30439764-A0952D5B-7E75-4D4B-88E8-2BC66B2A4A88Q33462060-6138F320-D6CA-41A3-97C0-36B4CDC54298Q33532670-D079729E-5227-47B5-8A8B-032E0BB7A757Q33614806-7CECCAE9-A307-4CF4-AA20-1E7431F4DCDCQ33618619-68D96FAF-D14E-447A-B5B9-D1354CBEDB5FQ33893309-FDCCA153-40CD-4319-93C5-FCBBC4706B62Q34051561-909AA951-B1BC-4CCF-B9BE-DAB67E2A714FQ34125508-45D3288E-0DD0-447D-BB20-D931E133B31AQ34219057-1A75D4CB-87AA-4CD2-84C8-88A0A42F882BQ34353144-E4D4EBFF-C4B5-40BB-91A9-C69531ADA4CFQ34363654-92C20D67-8CC2-4834-BD40-9C31C244B562Q34496411-D5DCE9B0-9562-4759-B3A5-A0B8C01E9CF7Q34620003-45F5D965-D7F9-40DE-8AF3-21DE23900BC4Q35007558-C470561A-E295-443D-B08A-C96A32EC5B65Q35022016-F0640221-EFBF-4462-9713-4B2DE90AFFDDQ35030040-A346092E-4EBA-4AC2-A885-8A10FD0B6C07Q36073502-BCB8DE74-0166-48D2-99B0-DEC983C177C4Q36141884-EEAE45A1-7F72-46AA-8F86-F64A52339557Q36944312-29296345-D8B9-4A0A-86B2-45324022BDB7Q37157134-18615189-D379-4743-9D04-61ABB87DD46DQ37279639-5FB0C608-3BFC-4647-B04A-90D74EE9ECF9Q37400453-504415E4-AEE2-4194-9B31-3B565DA2A53DQ37663453-17163994-3B87-4B59-B5E6-728EE54B21EDQ37942600-48C886C8-BB0F-43E0-9FAD-93C93CA5F1D3Q37976449-EF0C3CD8-1F7A-4AD6-8481-54704BFFE92EQ38001506-F8DAE54A-A4CA-44AB-ADEB-04EF3272EAF4Q38095938-CBCDD722-59E0-41FC-9583-A48442B8F030Q38432111-956421F3-7E7E-40BB-AB32-59FE5557CA22Q38564798-7EDB8EBA-063E-4778-B2F1-86F890DFDFEEQ38936941-29AF79AF-4FF8-47B4-B61E-DD899D20DED5Q40035321-04A9CB92-ABE5-44BD-9ADF-66A64F4C97B5Q40083151-900CB550-04D3-4EF6-A20E-103EE5C22EC0Q41367762-9292F7DF-0057-4223-B6BA-32265B45B529Q41906508-87094B46-8A8E-4DC8-A4B2-D19A11F201BEQ42158202-C48033AA-743D-4C7D-B961-CE2DAB471A37Q42181707-A7FBCE45-CB11-4B4C-B504-6B0A258D0127
P2860
Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@en
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@nl
type
label
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@en
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@nl
prefLabel
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@en
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@nl
P2093
P1433
P1476
Unblinded pilot study of autol ...... th thromboangiitis obliterans.
@en
P2093
Hiroshi Nonogi
Kazuhiro Nishigami
Koichi Akutsu
Koji Miyamoto
Masaaki Chiku
Masahiro Higashi
Masataka Kamei
Noritoshi Nagaya
Ryoichi Tanaka
Satoshi Takeshita
P304
P356
10.1161/CIRCULATIONAHA.106.644203
P407
P577
2006-12-04T00:00:00Z